contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


hospital-in-finland-orders-nexstim-nbs-6-system

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Nexstim on vuonna 2000 perustettu suomalainen kansainvälisillä markkinoilla toimiva terveysteknologiayhtiö, jonka tuotteet mahdollistavat aivokuoren toiminnallisten alueiden kartoituksen ja halutun aivoalueen tarkan stimuloinnin sähkökentän avulla. Nexstimin liiketoiminta jakaantuu diagnostiikka- (Navigated Brain Stimulation NBS) ja terapia (Navigated Brain Therapy NBT) -liiketoimintoihin. Yhtiö on hiljattain alkanut tarjota asiakkailleen myös yhdistelmälaitteistoja, jotka sisältävät sekä NBS- että NBT-toiminnallisuudet. Nexstimillä on asiakkaita useassa kymmenessä maassa.

Kalkkiviivoille taitaa taas mennä, mutta niinhän se meni viime vuonnakin:

canhealth.com              CABHI awards $2.8M to advance the brain economy | Canadian Healthcare Technology    TORONTO - The Centre for Aging + Brain Health Innovation (CABHI), powered by Baycrest, has allocated $2.8 million CAD in funding to eight early- to mid-stage researchers and companies through its Fuel program to accelerate cutting-edge aging and...                             Sinapticalle rahaa.

Biostock – 3 Dec 25              Nexstim: from Helsinki to a global brain revolution    Finnish Nexstim's vision is to offer personalized diagnostics and therapy for serious brain diseases and disorders. To achieve this, it has developed a non-invasive technology for brain stimulation. The treatment works by inducing a weak electrical...         Estimated reading time: 8 minutes

linkedin.com              #neuromodulation #alzheimers #defaultmodenetwork #medtech #ctad25 | Sinaptica...    Today at the 18th Clinical Trials on Alzheimer's Disease (CTAD) in San Diego, Giacomo Koch, MD, PhD, Sinaptica scientific co-founder, and Lisa Fosdick, MS, Chief Clinical & Strategy Officer, will present a poster on our upcoming Phase 3 RETAIN...                             Sinaptica linkkarissa. Toivottavasti tämä esitys julkaistaan jossain.

Tuohon osakkeenomistajarekisteriin on tullut ilmeisesti joku päivitys ja sen takia näyttää väärin. Leenalla on kyllä yhtä monta lappua kun aiemminkin, mutta etunimi ja sukunimi ovat vaan vaihtaneet paikkaa.

Olipa Leena Niemistökin ostanu henk koht lappua, muttei vissiin ole mitään tiedotetta tarvinnut laittaa?

Skandinaviska Enskilda Banken Ab (publ) Helsingin Sivukonttori on lisännyt viime kuussa 25 922 osaketta. Omistajaan asti tuo tieto ei välity, mutta yksi nyanssi on se, että myös Brainlabin omistukset on tuolla samassa hallintarekisterissä. 14,50€ keskihinnalla noiden lappujen hankinta olisi ollut yhteensä 375 869€, eli isot pojat(tai tytöt) siellä joka tapauksessa ovat tankkaamassa.                   nexstim.com              Nexstim - Nexstimin suurimmat osakkeenomistajat

Nexstim

Press release, Helsinki, 27 October 2025 at 9 AM (EET) Hospital in Finland Orders Nexstim NBS 6 SystemNexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS 6 system...

Press release, Helsinki, 27 October 2025 at 9 AM (EET)&nbsp;Hospital in Finland Orders Nexstim NBS 6 SystemNexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS 6 system from an existing customer in Finland. The order concerns an upgrade of the customer’s previous Nexstim system.Earlier in October, the Nexstim received MDR (Regulation (EU) 2017/745) certification for the NBS 6 for the pre-procedural mapping of the speech and motor cortices of the brain. The NBS 6 system is also CE-marked for the treatment of major depression and chronic neuropathic pain in the EU.NBS 6 is a new combination system built on Nexstim's unique, clinically established E-field navigated TMS (transcranial magnetic stimulation) technology, with a modular system concept that allows system capabilities to expand over time and be highly customized based on a customer’s research or clinical interests.&nbsp;Mikko Karvinen, CEO of Nexstim, comments: “We are excited to announce the first order for an NBS 6 combination system since the launch a couple of weeks ago. Saturday October 25 marked Nexstim’s 25th anniversary. I would like to thank everyone that has contributed to Nexstim’s journey along the way. With roots in the long tradition on the multidisciplinary research of biomagnetism and neuroscience in Finland, we are happy to have a continued strong presence in our home market.”Further information is available on the website www.nexstim.com, or by contacting: Mikko Karvinen, CEO+358 50 326 4101mikko.karvinen@nexstim.com&nbsp;About Nexstim PlcNexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE-marked for the treatment of major depression and chronic neuropathic pain.Nexstim shares are listed on Nasdaq First North Growth Market Finland.For more information, please visit&nbsp;<a href="http://www.nexstim.com/">www.nexstim.com</a> <div> <hr> <div>Attachments</div> <div><a href="https://storage.googleapis.com/inderes-widgets-prod-assets/nexstim/attachments/01f59a30-e4e8-40f5-a730-eb79df7f65d2/nexstim-plc-press-release-fin-order-27102025-final.pdf">Nexstim Plc_Press release_Fin order_27102025_FINAL.pdf</a></div> </div>